



Press Note

India, Hyderabad; 03 December, 2022

Hetero Biopharma Launched “Herti” a Biosimilar Version of Trastuzumab

Hetero, a globally renowned vertically integrated pharmaceutical organization announced today that its biologics arm Hetero Biopharma launched ‘**Herti**’ a biosimilar version of Trastuzumab in India market. “**Herti**” approved for the treatment of patients with HER-2 positive breast cancer. “**Herti**” contains the active substance Trastuzumab, which is a humanised monoclonal antibody that binds to the HER-2 protein that inhibits the proliferation of human tumor cells that overexpress HER-2.

“**Herti**” is available as a combi-pack, which contains one vial of Trastuzumab (lyophilised powder for IV infusion) and one vial of Bacteriostatic water for injection, available in two presentations of 150mg and 440mg. The finished product contains trastuzumab as active substance along with L-Histidine Hydrochloride Monohydrate, L-Histidine, Trehalose dihydrate, and polysorbate 20. “**Herti**” administrated as Intravenous infusion after reconstitution with Bacteriostatic water for injection.

“**Herti**” is manufactured in the state-of-the-art GMP facility of Hetero Biopharma, Jadcherla, Telangana. With the launch of “**Herti**”, Hetero Biopharma have indigenously developed 5th Monoclonal Antibody and its 6th biosimilar in the domestic market and several other in the pipeline.

About Company:

Hetero is a globally renowned vertically integrated pharmaceutical organization engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.



Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide

Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment. For more information on Hetero, please visit www.heteroworld.com.

For further details, please contact:

Name:

Designation:

Contact Details